We identified and published a CD206-targeting peptide, called “mUNO”, that binds to mouse and human CD206 (83), is selective to mouse and human CD206+ macrophages (84), and delivers payload specifically to M2-like TAMs in mouse models of melanoma, glioblastoma, gastric carcinoma, and breast cancer (83) with very low accumulation in healthy organs (83, 85). Here, MRC1 is linked to breast cancer.